Literature DB >> 17586510

Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo.

Rajesh Puranik1, Shisan Bao2, Estelle Nobecourt3, Stephen J Nicholls3, Gregory J Dusting4, Philip J Barter1, David S Celermajer1, Kerry-Anne Rye5.   

Abstract

This study investigates the ability of a single, low dose of apolipoprotein (apo) A-I, the main lipoprotein of high density lipoproteins (HDL), to inhibit acute vascular inflammation in normocholesterolemic New Zealand White rabbits. Acute vascular inflammation was induced in the animals by placing a non-occlusive, silastic collar around the left common carotid artery. The animals (n=5/group) received a single, low dose infusion of saline or lipid-free apoA-I at the time of, or 3 or 9h after collar insertion. The animals were sacrificed 24h post-collar insertion. Inflammatory markers in the artery wall were quantitated immunohistochemically. The saline-treated animals exhibited substantial pan-arterial inflammation, which was inhibited by a single apoA-I infusion (2 or 8 mg/kg) at the time of collar insertion. A single 8 mg/kg infusion of lipid-free apoA-I administered 3h post-collar insertion reduced neutrophil recruitment into the vessel wall, and MPO expression, as well as endothelial expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) by >85% (p<0.01 for all). A single 8 mg/kg infusion of lipid-free apoA-I administered 9h after collar insertion decreased VCAM-1 expression, neutrophil infiltration and MPO expression by 88% (p<0.001), 47% (p<0.01), and 90% (p<0.01), respectively. This indicates that a single low dose infusion of apoA-I administered after the onset of acute inflammation in carotid arteries decreases neutrophil infiltration and inhibits neutrophil and endothelial cell activation. These findings have potential implications for treating acute vascular inflammation in conditions such as acute coronary and stroke syndromes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17586510     DOI: 10.1016/j.atherosclerosis.2007.05.008

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  30 in total

Review 1.  The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?

Authors:  Menno Vergeer; Adriaan G Holleboom; John J P Kastelein; Jan Albert Kuivenhoven
Journal:  J Lipid Res       Date:  2010-04-06       Impact factor: 5.922

Review 2.  New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease.

Authors:  Philip J Barter; Rajesh Puranik; Kerry-Anne Rye
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

Review 3.  Cardioprotective functions of HDLs.

Authors:  Kerry-Anne Rye; Philip J Barter
Journal:  J Lipid Res       Date:  2013-06-27       Impact factor: 5.922

Review 4.  High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease.

Authors:  Meliana Riwanto; Ulf Landmesser
Journal:  J Lipid Res       Date:  2013-07-20       Impact factor: 5.922

5.  A thumbwheel mechanism for APOA1 activation of LCAT activity in HDL.

Authors:  Allison L Cooke; Jamie Morris; John T Melchior; Scott E Street; W Gray Jerome; Rong Huang; Andrew B Herr; Loren E Smith; Jere P Segrest; Alan T Remaley; Amy S Shah; Thomas B Thompson; W Sean Davidson
Journal:  J Lipid Res       Date:  2018-05-17       Impact factor: 5.922

6.  High-Density Lipoprotein Proteomics: Identifying New Drug Targets and Biomarkers by Understanding Functionality.

Authors:  Scott Gordon; Anita Durairaj; Jason L Lu; W Sean Davidson
Journal:  Curr Cardiovasc Risk Rep       Date:  2010

Review 7.  Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond.

Authors:  Amy S Shah; Lirong Tan; Jason Lu Long; W Sean Davidson
Journal:  J Lipid Res       Date:  2013-02-24       Impact factor: 5.922

Review 8.  Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells.

Authors:  Andrew J Murphy; Marit Westerterp; Laurent Yvan-Charvet; Alan R Tall
Journal:  Biochim Biophys Acta       Date:  2011-08-16

9.  Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

Authors:  Estelle Nobécourt; Fatiha Tabet; Gilles Lambert; Rajesh Puranik; Shisan Bao; Ling Yan; Michael J Davies; Bronwyn E Brown; Alicia J Jenkins; Gregory J Dusting; David J Bonnet; Linda K Curtiss; Philip J Barter; Kerry-Anne Rye
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-01-28       Impact factor: 8.311

10.  The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro.

Authors:  Fatiha Tabet; Alan T Remaley; Aude I Segaliny; Jonathan Millet; Ling Yan; Shirley Nakhla; Philip J Barter; Kerry-Anne Rye; Gilles Lambert
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-12-03       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.